Literature DB >> 198122

Inhibition of B-16 melanoma growth in vivo by a synthetic analog of prostaglandin E2.

M G Santoro, G W Philpott, B M Jaffe.   

Abstract

The effect of systemic administration of 16,16-dimethyl prostaglandin E2-methyl ester (di-M-PGE2) on the growth of B-16 melanoma tumors has been studied in C57BL/6J mice. Daily i.p. injection of 5 mu of di-M-PGE2 commencing on the day of tumor inoculation with 10(5) and 10(6) viable cells delayed appearance of tumors; for the smaller tumor inoculum, it also increased median survival among treated mice from 23 to 33 days. Di-M-PGE2 treatment of mice with established tumors caused significant inhibition of tumor growth, as measured by a number of parameters including tumor diameters and volumes. At the time of sacrifice, di-M-PGE2-treated mice had tumors that were an average of 32% smaller (by weight), contained 60% fewer melanoma cells, and had higher concentrations of cyclic adenosine 3':5'-monophosphate and cyclic guanosine 3':5'-monophosphate (+225% and +100%, respectively).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 198122

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Inhibition of tumor growth and metastasis by chronic intravenous infusion of prostaglandin E1.

Authors:  L M Ellis; E M Copeland; K I Bland; H S Sitren
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

2.  Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture.

Authors:  B K Bhuyan; G J Badiner; E G Adams; R Chase
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

3.  Homeobox protein HB9 binds to the prostaglandin E receptor 2 promoter and inhibits intracellular cAMP mobilization in leukemic cells.

Authors:  Sarah Wildenhain; Deborah Ingenhag; Christian Ruckert; Özer Degistirici; Martin Dugas; Roland Meisel; Julia Hauer; Arndt Borkhardt
Journal:  J Biol Chem       Date:  2012-10-08       Impact factor: 5.157

4.  Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer.

Authors:  T Yoshida; S Ohki; M Kanazawa; H Mizunuma; Y Kikuchi; H Satoh; Y Andoh; A Tsuchiya; R Abe
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

5.  Effect of endogenous and exogenous prostaglandin E on Friend erythroleukaemia cell growth and differentiation.

Authors:  M G Santoro; A Benedetto; B M Jaffe
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

6.  Inhibition of Friend erythroleukaemia-cell tumours in vivo by a synthetic analogue of prostaglandin E2.

Authors:  M G Santoro; B M Jaffe
Journal:  Br J Cancer       Date:  1979-04       Impact factor: 7.640

7.  Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin.

Authors:  A Bennett; M A Carroll; P B Melhuish; I F Stamford
Journal:  Br J Cancer       Date:  1985-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.